Skip to content

Effects of Preoperative Long-Term Immunonutrition in Patients Listed for Liver Transplantation

Randomized Controlled Double Blind Multi-Center Clinical Trial to Assess the Effects of Preoperative Long-Term Immunonutrition in Patients Listed for Liver Transplantation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00495859
Acronym
PROUD
Enrollment
156
Registered
2007-07-03
Start date
2008-04-30
Completion date
2011-04-30
Last updated
2008-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly Registered Patients for Primary Liver Transplantation

Keywords

Immunonutrition, immune enhancing diets, arginine, ω-3 fatty acids, nucleotides, liver transplantation, clinical trial

Brief summary

Patients with endstage liver disease characteristically are malnourished which is associated with poor outcome. Formulas enriched with arginine,ω3 fatty acids, and nucleotides potentially improve their nutritional status. This randomized placebo-controlled double blind multicenter clinical trial with longterm preoperative supplementation with such an enriched formula will evaluate evaluate effects of such formulas on patients' quality of life, survival, and posttransplant morbidities.

Detailed description

Background. Patients with end stage liver disease characteristically are malnourished which is associated with poor outcome. Formulas enriched with arginine, ω-3 fatty acids, and nucleotides, immunonutrients, potentially improve their nutritional status. This study is designed to evaluate the clinical outcome of long-term immunonutrition of patients with end-stage liver disease while on the waiting list for liver transplantation. Methods / design. A randomized controlled double blind multi-center clinical trial with two parallel groups comprising a total of 142 newly registered patients for primary liver transplantation has been designed to assess the safety and efficacy of the long-term administration of ORAL IMPACT®, an immunonutrient formula, while waiting for a graft. Patients will be enrolled the day of registration on the waiting list for liver transplantation. Study ends on the day of transplantation. Primary endpoints include patients' nutritional and physiological status, as measured by mid-arm muscle area, triceps skin fold thickness, grip strength, and fatigue score, as well as patients' health related quality of life. Furthermore, patients will be followed for 12 postoperative weeks to evaluate anabolic recovery after transplantation as shown by reduced post-transplant mechanical ventilation, hospital stay, wound healing, infectious morbidities (pneumonia, intra-abdominal abscess, sepsis, line sepsis, wound infection, and urinary tract infection), acute and chronic rejection, and mortality. Discussion. Formulas enriched with arginine, ω-3 fatty acids, and nucleotides have been proven to be beneficial in reducing postoperative infectious complications and length of hospital stay among the patients undergoing elective gastrointestinal surgery. Possible mechanisms include downregulation of the inflammatory responses to surgery and immune modulation rather than a sole nutritional effect.

Interventions

DIETARY_SUPPLEMENTImmunonutrition

food for special medical purpose (FSMP)

DIETARY_SUPPLEMENTfood for special medical purposes (FSMP)

an isocaloric isonitrogenous non-specific nutritional support

Sponsors

Novartis
CollaboratorINDUSTRY
Heidelberg University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 68 Years
Healthy volunteers
No

Inclusion criteria

* Men and women between 18 and 68 years of age * Scheduled for first liver transplantation * Written informed consent * Protein-calorie malnutrition: Mid-arm muscle area (MAMA) \<85% standard

Exclusion criteria

* Patients \< 18 and \> 68 years * Pregnant or nursing women * History of hypersensitivity to arginine, ω-3 fatty acids, or nucleotides * Inability to take oral nutrition * Patients with fulminant or subacute hepatic failure requiring urgent transplantation * Mental condition rendering the subject incapable to understand the nature, scope, and consequences of the trial * Simultaneous participation in another clinical trial

Design outcomes

Primary

MeasureTime frame
improved patients' nutritional and physiological status, fatigue score, as well as patients' health related quality of life.while in the waiting list for liver transplantation

Secondary

MeasureTime frame
enhanced anabolic recovery after transplantation as shown by reduced post-transplant morbidities and mortalitiesthe first 12 posttransplant weeks

Countries

Germany

Contacts

Primary ContactPeter Schemmer, MD
peter.schemmer@med.uni-heidelberg.de004962215636500
Backup ContactArash Nickkholgh, MD
arash.nickkholgh@med.uni-heidelberg.de004962215638584

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026